performed a proof-of-principle trial where they supplemented RT with subcutaneous GM-CSF, a cytokine that promotes dendritic cell differentiation and expansion, in patients with metastatic tumors including breast cancer, bladder cancer, and eccrine cancer (51, 62). The gene discussed is CSF2; the disease is breast cancer.